Samarium-153-ethylene diamine tetramethylene phosphonate

Revision as of 15:51, 20 August 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

WikiDoc Resources for Samarium-153-ethylene diamine tetramethylene phosphonate

Articles

Most recent articles on Samarium-153-ethylene diamine tetramethylene phosphonate

Most cited articles on Samarium-153-ethylene diamine tetramethylene phosphonate

Review articles on Samarium-153-ethylene diamine tetramethylene phosphonate

Articles on Samarium-153-ethylene diamine tetramethylene phosphonate in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Samarium-153-ethylene diamine tetramethylene phosphonate

Images of Samarium-153-ethylene diamine tetramethylene phosphonate

Photos of Samarium-153-ethylene diamine tetramethylene phosphonate

Podcasts & MP3s on Samarium-153-ethylene diamine tetramethylene phosphonate

Videos on Samarium-153-ethylene diamine tetramethylene phosphonate

Evidence Based Medicine

Cochrane Collaboration on Samarium-153-ethylene diamine tetramethylene phosphonate

Bandolier on Samarium-153-ethylene diamine tetramethylene phosphonate

TRIP on Samarium-153-ethylene diamine tetramethylene phosphonate

Clinical Trials

Ongoing Trials on Samarium-153-ethylene diamine tetramethylene phosphonate at Clinical Trials.gov

Trial results on Samarium-153-ethylene diamine tetramethylene phosphonate

Clinical Trials on Samarium-153-ethylene diamine tetramethylene phosphonate at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Samarium-153-ethylene diamine tetramethylene phosphonate

NICE Guidance on Samarium-153-ethylene diamine tetramethylene phosphonate

NHS PRODIGY Guidance

FDA on Samarium-153-ethylene diamine tetramethylene phosphonate

CDC on Samarium-153-ethylene diamine tetramethylene phosphonate

Books

Books on Samarium-153-ethylene diamine tetramethylene phosphonate

News

Samarium-153-ethylene diamine tetramethylene phosphonate in the news

Be alerted to news on Samarium-153-ethylene diamine tetramethylene phosphonate

News trends on Samarium-153-ethylene diamine tetramethylene phosphonate

Commentary

Blogs on Samarium-153-ethylene diamine tetramethylene phosphonate

Definitions

Definitions of Samarium-153-ethylene diamine tetramethylene phosphonate

Patient Resources / Community

Patient resources on Samarium-153-ethylene diamine tetramethylene phosphonate

Discussion groups on Samarium-153-ethylene diamine tetramethylene phosphonate

Patient Handouts on Samarium-153-ethylene diamine tetramethylene phosphonate

Directions to Hospitals Treating Samarium-153-ethylene diamine tetramethylene phosphonate

Risk calculators and risk factors for Samarium-153-ethylene diamine tetramethylene phosphonate

Healthcare Provider Resources

Symptoms of Samarium-153-ethylene diamine tetramethylene phosphonate

Causes & Risk Factors for Samarium-153-ethylene diamine tetramethylene phosphonate

Diagnostic studies for Samarium-153-ethylene diamine tetramethylene phosphonate

Treatment of Samarium-153-ethylene diamine tetramethylene phosphonate

Continuing Medical Education (CME)

CME Programs on Samarium-153-ethylene diamine tetramethylene phosphonate

International

Samarium-153-ethylene diamine tetramethylene phosphonate en Espanol

Samarium-153-ethylene diamine tetramethylene phosphonate en Francais

Business

Samarium-153-ethylene diamine tetramethylene phosphonate in the Marketplace

Patents on Samarium-153-ethylene diamine tetramethylene phosphonate

Experimental / Informatics

List of terms related to Samarium-153-ethylene diamine tetramethylene phosphonate


Overview

Samarium-153-ethylene diamine tetramethylene phosphonate, Samarium-153 EDTMP, or simply Samarium-153 is a complex of a radioisotope of the lanthanide element Samarium with carrier EDTMP which is used to treat pain when cancer has spread to the bone. Samarium-153 is injected into a vein and distributes throughout the body. Samarium-153 EDTMP homes in on areas where cancer has invaded the bone. Once there, the radioisotope emits beta particles (electrons) which kill the nearby cancer cells. Pain begins to improve in the first week for most people and the effects can last several months. It is commonly used in lung cancer, prostate cancer, breast cancer, and osteosarcoma. Side effects result from radiation to the bone marrow and include thrombocytopenia and leukopenia.

References

Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005 Jun;6(6):392-400. Review. PMID 15925817

Anderson P. Samarium for osteoblastic bone metastases and osteosarcoma. Expert Opin Pharmacother 2006; 7:1475-86.

Template:WikiDoc Sources